COMPANY

Spineology

HQ: St. Paul, MN source · spineology.com ↗ · Midwest

Location: St. Paul, MN · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Lumbar Degenerative Disc Disease Degeneration of Lumbar Intervertebral Disc

Funding and NIH signals

SEC Form D raise Raised $12.64M (Form D filed Nov 19, 2025; amended Jun 17, 2026). SEC Form D 0001165842-25-000003 (Nov 19, 2025)
Evidence (1 event)
- Nov 19, 2025 · SEC Form D 0001165842-25-000003
  Name of Issuer: SPINEOLOGY INC; CIK: 1165842; Address: St. Paul, MN; Submission type: D; Filing date: 2025-11-19; Industry Group: Biotechnology; Date of First Sale: 2025-11-07; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10522826; Total Amount Sold: 8755306; Federal exemptions: 06b || Name of Issuer: SPINEOLOGY INC; CIK: 1165842; Address: St. Paul, MN; Submission type: D/A; Filing date: 2026-06-17; Industry Group: Biotechnology; Date of First Sale: 2025-11-07; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 14079337; Total Amount Sold: 12641849; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raise Series AA · $25M · announced Aug 6, 2024 Company release ↗
Source quote
- Aug 6, 2024 · Company release ↗
  “Spineology, the medical technology company pioneering Conform and Expand™ technology, today announced that it has raised $25 million in Series AA financing led by SV Health Investors, with participation from 1315 Capital and its existing investor, RC Capital.”

Raises announced in these releases: $25M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Dec 15, 2025 FDA FDA 510(k) clearance: OptiMesh Multiplanar Expandable Interbody Fusion System — K251302, Dec 15, 2025. Applicant at approval: Spineology, Inc. source ↗
Dec 4, 2025 FDA FDA 510(k) clearance: Spineology Navigation Instruments — K251943, Dec 4, 2025. Applicant at approval: Spineology, Inc. source ↗
Aug 6, 2024 Raise Series AA · $25M source ↗
Oct 2, 2017 Trial start —: Rampart Duo Clinical (RaDical) Post-Market Study source ↗
Jan 22, 2015 Trial start Not phased (device or behavioral study): Spineology Clinical Outcomes Trial: An IDE Investigation source ↗
2003-07 Trial start Not phased (device or behavioral study): OptiMesh® for Lumbar Interbody Fusion Trial (OLIF) source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT03974711	Rampart Duo Clinical (RaDical) Post-Market Study	Not listed	Completed	Oct 2, 2017	Apr 21, 2022 (actual)
NCT02347410	Spineology Clinical Outcomes Trial: An IDE Investigation	Not phased (device or behavioral study)	Completed	Jan 22, 2015	Jan 22, 2020 (actual)
NCT00764491	OptiMesh® for Lumbar Interbody Fusion Trial (OLIF)	Not phased (device or behavioral study)	Completed	2003-07	2012-11 (actual)

Dec 15, 2025 FDA 510(k) clearance: OptiMesh Multiplanar Expandable Interbody Fusion System — K251302, Dec 15, 2025. Applicant at approval: Spineology, Inc. source ↗
Dec 4, 2025 FDA 510(k) clearance: Spineology Navigation Instruments — K251943, Dec 4, 2025. Applicant at approval: Spineology, Inc. source ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12